Reprogramming compromised immune cells to fight cancer
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...
The Scientist6mon
Cell-Based Assays for Immuno-Oncology
Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer ... an ...
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...
Hosted on MSN2mon
Treatment method does not improve survival for mantle cell lymphoma patients, clinical trial shows
The finding is from the phase 3 study EA4151, Rituximab With or Without Stem Cell ... cancer cells using the clonoSEQ MRD test. This highly sensitive commercial minimal residual disease (MRD ...
Renal & Urology News6d
Noninvasive Assay Predicts Treatment Outcomes in Metastatic Urothelial Cancer
Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer ... of total cell-free DNA (cfDNA ...
The Scientist12d
Considerations for Cell-Based Assays in Immuno-Oncology Research
In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.